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Abstract
Background: The need to review cervical cancer prevention strategies has been triggered by the availability of
new prevention tools linked to human papillomavirus (HPV): vaccines and screening tests. To consider these
innovations, information on HPV type distribution and natural history is necessary. This is a five-year follow-up
study of gynecological high-risk (HR) HPV infection among a Chilean population-based cohort of women.
Findings: A population-based random sample of 969 women from Santiago, Chile aged 17 years or older was
enrolled in 2001 and revisited in 2006. At both visits they answered a survey on demographics and sexual history
and provided a cervical sample for HPV DNA detection (GP5+/6+ primer-mediated PCR and Reverse line blot
genotyping). Follow-up was completed by 576 (59.4%) women; 45 (4.6%) refused participation; most losses to
follow-up were women who were unreachable, no longer eligible or had missing samples. HR-HPV prevalence
increased by 43%. Incidence was highest in women < 20 years of age (19.4%) and lowest in women > 70 (0%); it
was three times higher among women HR-HPV positive versus HPV negative at baseline (25.5% and 8.3%; OR 3.8,
95% CI 1.8-8.0). Type-specific persistence was 35.3%; it increased with age, from 0% in women < 30 years of age to
100% in women > 70. An enrollment Pap result ASCUS or worse was the only risk factor for being HR-HPV positive
at both visits.
Conclusions: HR-HPV prevalence increased in the study population. All HR-HPV infections in women < 30 years
old cleared, supporting the current recommendation of HR-HPV screening for women > 30 years.
Background
Most research on the natural history of human papillo-
mavirus (HPV) infection and its progression towards
cancer has been conducted in developed areas. In Chile,
a middle developing country, the only two population-
based studies to date analyzed the prevalence of HPV at
one point in time [1,2]. Chile has a well-organized
nationwide cervical cancer prevention program based on
Papanicolaou screening, which, after an initial impact on
cervical cancer mortality, has not produced a significant
decrease in the last decade [3]. Moreover, Chile cur-
rently has a high socioeconomic status differential in
cervical cancer mortality (C. Ferreccio, unpublished
observations). The need to review prevention programs
has been triggered by the availability of two new effec-
tive prevention tools linked to HPV: vaccines and
screening tests. To consider these innovations, countries
should have baseline information on HPV type distribu-
tion in their populations, as well as knowledge of how
these infections evolve.
Methods
In 2001 we studied the prevalence of gynecological HPV
among a population-based sample of 969 women 17
years of age and older, from a low socio-economic
urban area of Santiago. Results and detailed description
of enrollment and data collection procedures were pre-
viously reported [1]. Five years later we re-examined
these women with the objectives of measuring high-risk
(HR) HPV prevalence at this second point in time, and
assessing rates and risk factors of HR-HPV persistence.
We attempted to contact these women for follow-up by
home visits: 182 were not reachable, 45 declined
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terectomy, recent surgery, death) and 144 were excluded
due to missing cervical samples. Therefore, data for the
present analysis was available for 576 women (59.4%).
At enrollment and follow-up, participants signed an
informed consent form and completed a questionnaire
on demographic and behavioral characteristics.
Participants attended a health center where a midwife
collected cervical samples for HPV testing. An Ayre spa-
tula was used to obtain exfoliated cervical cells and then
placed in a tube with PBS; additionally, a spatula and cyto-
brush used for a Pap smear obtained at the same visit
were washed in this tube. In both 2001 and 2006, HPV
DNA testing was performed at the Department of Pathol-
ogy of the VU University Medical Center in Amsterdam,
the Netherlands. Specimens were tested for the presence
of HPV DNA using a GP5+/6+ primer-mediated PCR and
enzyme immune assay. Reverse line blot genotyping was
used to type for 44 HPV genotypes, 14 HR-HPV (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) [4].
Multivariate comparison of participants and non-partici-
pants in the follow-up examination was performed using
logistic regression to identify predictors of participation.
Prevalence of HR-HPV infection in 2001 and 2006 was
compared, using prevalence rate ratios. Risk factors for
HR-HPV incidence and persistence (age, marital status,
schooling, number of children, age of first sexual inter-
course, lifetime number of sexual partners, high-risk sexual
partner, condom use, history of sexually transmitted dis-
ease, hormonal contraception, smoking, history of previous
Pap tests, and an abnormal baseline Pap test) were exam-
ined with univariate analysis; variables significant at P
value < 0.2 were then entered in multivariate models. Sex-
ual behavioral changes in the study period were explored
as risk factors for HR-HPV incidence. Statistical analyses
were performed using SPSS version 17 for Windows.
Results
Sociodemographic characteristics of the study sample are
presented in Table 1. Because it was not initially designed
as a prospective study, we could only recontact 59% of
the original cohort; losses to follow-up were mainly due
to changes in address (182) or loss of cervical samples
(144). Among participants in the follow-up study, lower
schooling and never using a condom were significantly
higher in multivariate analysis (OR 1.94, 95% CI 1.2-3.2
and OR 2.00, 95% CI 1.0-3.9 respectively).
The HR-HPV infections identified in the participants
at baseline and follow-up are presented in Table 2. HR-
HPV infection increased by 43%, from 8.8% to 12.7%.
H P V 1 6p r e v a l e n c ed i dn o tc h a n g em a r k e d l yi nt h ep e r -
iod (2.1% - 3.3%); the largest increase of a particular
HR-HPV genotype was for HPV18 (0.5% to 2.8%),
which became the second most common HR-HPV in
2006 (fifth in 2001).
Prevalence, incidence and persistence of HR-HPV
infections according to baseline age groups are pre-
sented in Table 3. In both years, HPV prevalence fol-
lowed a U-curve, being highest at ages under 20 years
(13.9% - 19.4%) and over 70 years (16.7% - 16.7%). Inci-
dence was highest in women under 20 years old (19.4%)
and lowest in women over 70 years old (0%). Incidence
of new HR-HPV among women HR-HPV positive at
baseline was three times higher (25.5%) than among
women HPV negative at baseline (8.3%) (OR 3.8, 95%
CI 1.8-8.0). In univariate analysis, baseline characteristics
significantly associated with acquiring new HR-HPV
types (n = 59), using women who did not acquire a HR-
HPV (n = 517) as referent, were being younger than 30
years and not having a previous Pap test (Table 1); only
the latter remained significant in multivariate analysis
(OR 0.36, 95% CI 0.15-0.88). Some behavioral changes
in the study period were associated with acquiring a
new HR-HPV, however they did not reach statistical sig-
nificance: becoming single or separated (OR 1.61, 95%
CI 0.75-3.45), having new sexual partners (OR 1.12, 95%
CI 0.46-2.74), having a new high-risk sexual partner
(OR 1.38, 95% CI 0.50-3.77) and beginning smoking
(OR 1.63, 95% CI 0.54-4.89).
Of the 576 participants, 27 (4.7%) tested positive for
any HR-HPV (regardless of type) both years and 427
(74.1%) were HPV negative both years. In univariate
analysis, baseline characteristics associated with non-
type-specific HR-HPV persistence, using women who
remained HR-HPV negative as referent, were low
schooling (OR 2.76, 95% CI 1.02-7.43) and an abnormal
baseline Pap test (OR 12.55, 95% CI 3.30-47.71); how-
ever, only the later remained significant in multivariate
analysis (OR 10.73, 95% CI 2.75-41.95).
HR-HPV type-specific persistence was 35.3%. All type-
specific persistence occurred in women older than 30
years of age, increasing from 33.3% in women 31-40
years old to 100% in women over 70 years old. Addi-
tionally, a significant association with type-specific HR-
HPV persistence (n = 18), in comparison with women
who cleared a HR-HPV infection (n = 33), was observed
with low schooling (Table 1); however, this did not
reach statistical significance in multivariate analysis. We
did not identify significant differences in persistence
rates among different HR-HPV types: 5 out of 15
(33.3%) HPV 16/18 infections persisted, compared with
13 out of 44 (29.5%) other HR-HPV infections.
Discussion
Reasons for the increase in HR-HPV infection are
unclear, especially since the increase in age of the study
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Page 2 of 6Table 1 Baseline characteristics associated with participation in follow-up study and with high-risk HPV infection outcome
Characteristic at enrollment in 2001 Category Participation in follow-up study HR-HPV infection outcome (Univariate)
Enrolled 2001 Followed 2006 Multivariate Type-specific Persistence Incidence
(n = 969)* (n = 576)* P value OR (95% CI)** OR (95% CI)***
Age < 30 years old 23.4 19.8 0.813 Inf 2.11 (1.17-3.80)
Marital Status Single/separated/widowed 24.4 20.7 0.169 0.18 (0.02-1.61) 0.40 (0.17-0.97)
Schooling ≤ 8 years 58.5 61.6 0.011 5.00 (1.21-20.69) 1.24 (0.70-2.19)
N° of Children ≥ 3 55.8 59.3 0.077 1.44 (0.43-4.85) 0.74 (0.43-1.28)
Age First Sexual Intercourse ≤16 years old 36.0 35.8 0.681 0.68 (0.21-2.17) 1.36 (0.79-2.36)
Lifetime Sexual Partners > 1 39.6 36.0 0.701 0.74 (0.23-2.34) 0.78 (0.43-1.41)
Current High-risk Sexual Partner
a Yes 31.0 29.8 0.311 1.93 (0.49-7.61) 0.60 (0.27-1.35)
Condom Use Never 84.0 85.5 0.045 0.18 (0.02-2.16) 0.90 (0.41-2.01)
History of STD
b Yes 3.8 4.2 0.222 1.88 (0.11-32.01) 0.36 (0.05-2.75)
Current Hormonal Contraception Yes 12.0 13.3 0.733 0.39 (0.10-1.54) 1.33 (0.75-2.38)
Current Smoker Yes 40.5 38.5 0.427 0.47 (0.14-1.55) 0.74 (0.42-1.31)
Previous Pap Test No 21.2 17.0 0.7 14.35 (0.78-262.64) 1.97 (1.06-3.67)
Abnormal Baseline Pap
c Yes 3.8 3.7 0.904 0.32 (0.06-1.68) 0.92 (0.21-4.05)
Baseline HPV Status HR-HPV positive 9.6 8.9 0.999 – 3.56 (1.77-7.16)
* values presented as percentages.
** referent: women who in 2006 had cleared a HR-HPV genotype present in 2001.
*** referent: women who did not acquire a new HR-HPV genotype in 2006.
a partner had sex with other women during their relationship or ever had sex with prostitute.
b sexually transmitted disease.
c ASCUS or worse.
Bold: statistically significant at P value < 0.05.
Inf: infinite odds ratio since the characteristic was present in 0% of cases; thus the CI is incalculable.
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6population should have produced a decline in the num-
ber of HR-HPV positive women. The same protocol for
HPV testing was used in both surveys and therefore the
increase in HPV prevalence could not be attributed to an
increase in sensitivity of HPV testing, but rather to an
increase in exposure to HPV. A possible explanation for
this is a change in sexual behavior; national health sur-
veys have shown an increasing lifetime number of sexual
partners among Chilean women [5]. In our cohort,
women who acquired new HR-HPV infections had a
greater increase in high-risk sexual behaviors than those
who did not, though this difference did not reach statisti-
cal significance. The observed increase in HR-HPV infec-
tions suggests that a close surveillance of these infections
and their associated lesions should be considered.
The age distribution of new infections showed a first
peak in the youngest and a second peak at age 45 to 55
years old at follow-up. This second peak has been pre-
viously described in other Latin American countries [6];
however its significance is unclear, as it could represent
newly acquired infections or dormant infections that
have resurfaced in relation to menopausal changes. Based
on the first hypothesis, some have recommended vacci-
nation for adult women [7], while the second hypothesis
suggests a more conservative approach. Answering this
question will require more mechanistic research.
HR-HPV type-specific persistence increased with age,
which is in line with findings reported in other studies
[8,9]. Our finding that all HR-HPV infection cleared in
women under age 30 indicates that the current recom-
mendation of HPV screening for women over 30 years
of age applies in our population [10,11].
Women with type-specific HR-HPV persistence are at
high risk of developing cervical cancer [12-15] and
should be under tight surveillance for precancerous
lesions; they represent 3.1% (18 out of 576) of our study
population. Our results indicate that if a screening pro-
gram were implemented using a test like Hybrid Cap-
ture 2, which does not identify specific types of HR-
HPV, 4.7% of our population would be called for further
work up, thus including the 1.6% of women who in fact
Table 2 High-risk HPV infections in a cohort of 576
women - Santiago, Chile
HR-HPV type 2001 2006 Prevalence Rate Ratio
women % women % 2006/2001 95% CI
Any HR-HPV 51 8.8 73 12.7 1.4 1.02 - 2.01
HPV 16 12 2.1 19 3.3 1.6 0.78 - 3.23
HPV 18 3 0.5 16 2.8 5.3 1.56 - 18.20
HPV 31 8 1.4 5 0.9 0.6 0.21 - 1.90
HPV 33 2 0.4 1 0.2 0.5 0.05 - 5.50
HPV 35 2 0.4 3 0.5 1.5 0.25 - 8.94
HPV 39 4 0.7 8 1.4 2.0 0.61 - 6.61
HPV 45 3 0.5 10 1.7 3.3 0.92 - 12.05
HPV 51 1 0.2 5 0.9 5.0 0.59 - 42.67
HPV 52 2 0.4 6 1.0 3.0 0.61 - 14.80
HPV 56 8 1.4 11 1.9 1.4 0.56 - 3.39
HPV 58 7 1.2 4 0.7 0.6 0.17 - 1.94
HPV 59 4 0.7 2 0.4 0.5 0.09 - 2.72
HPV 66 2 0.4 2 0.4 1.0 0.14 - 7.08
HPV 68 1 0.2 0 0.0 0.0 –
Bold: statistically significant.
Table 3 High-risk HPV status after 5 years in a cohort of 576 women - Santiago, Chile
Age
in 2001
years
Number
of
women
Prevalence Incidence Persistence
2001
n (%)
2006
n (%)
n (%) any type type-specific
n (%) % of cohort n (%) % of cohort
≤ 20 36 5 (13.9) 7 (19.4) 7 (19.4) 0 (0.0) 0.0 0 (0.0) 0.0
21 - 30 84 8 (9.5) 12 (14.3) 12 (14.3) 2 (25.0) 2.4 0 (0.0) 0.0
31 - 40 112 9 (8.0) 9 (8.0)* 7 (6.2) 4 (44.4) 3.6 3 (33.3) 2.7
41 - 50 157 9 (5.7) 21 (13.4) 17 (10.8) 6 (66.7) 3.8 4 (44.4) 2.5
51 - 60 111 12 (10.8) 14 (12.6)* 11 (9.9) 7 (58.3) 6.3 5 (41.7) 4.5
61 - 70 58 5 (8.6) 7 (12.1)* 5 (8.6) 5 (100) 8.6 3 (60.0) 5.2
> 70 18 3 (16.7) 3 (16.7) 0 (0.0) 3 (100) 16.7 3 (100) 16.7
All 576 51 (8.9) 73 (12.7)* 59 (10.2) 27 (52.9) 4.7 18 (35.3) 3.1
Prevalence: women testing positive for one or more high-risk HPV genotypes in a given year.
Incidence: women with one or more newly detected high-risk HPV genotypes in 2006.
Persistence, any type: women testing positive for one or more high-risk HPV genotypes in both 2001 and 2006, regardless of genotype.
Persistence, type-specific: women testing positive for the same high-risk HPV genotype(s) in both 2001 and 2006.
* The number of incident cases plus the number of type-specific persistent cases does not equal the number of prevalent cases because some women have
both a persistent high-risk HPV genotype and a newly detected one.
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bly unnecessary follow-up could be avoided if a type-
specific test were used, but this should be balanced
against the higher cost of the test. Recent studies con-
ducted in Canada [16], Mexico [17], South Africa [18],
Europe and the US [19] have shown that implementa-
tion of an HPV screening strategy, even without geno-
typing, can be highly cost effective when compared with
cytology screening alone.
A major strength of this study is that it is the first in
Chile that follows a population-based cohort of women
to learn about the natural history of HR-HPV infection
in our population. Other strengths include the broad
age range of enrolled women, the collection of compre-
hensive information on risk factors, and the perfor-
mance of DNA testing at a world reference laboratory.
In conclusion, HR-HPV prevalence in our study popu-
lation increased during the follow-up period, presumably
the result of changes in sexual behavior, which could
lead to an increase in cervical cancer in this population.
In order to strengthen our prevention programs, newly
available tools such as HPV-based screening tests should
be considered in Chile. In our study, all HR-HPV infec-
tions in women under 30 years old cleared, supporting
the current recommendation of HR-HPV screening for
women over 30 years of age.
Abbreviations
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